Argenx (ARGX) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argenx (ARGX) is launching a Phase 2 clinical study evaluating ARGX-119 IV for pediatric patients aged 5 to 18 with Spinal Muscular Atrophy (SMA). The study aims to determine the correct dosage of ARGX-119, assess its safety, efficacy, pharmacokinetics, and immunogenicity, while addressing the urgent medical needs in this condition.
ARGX-119 IV, a biological treatment, is designed for intravenous infusion to potentially modify disease progression. It will be tested against a placebo during the study’s double-blinded treatment period, followed by an open-label active-treatment extension phase where all participants will receive ARGX-119 for up to 100 weeks.
The study follows a randomized, parallel-group design with double masking, ensuring unbiased results during the 24-week treatment phase. All patients will continue disease-modifying therapies as standard care while participating. The study’s primary purpose is treatment-focused.
The trial is set to begin on December 15, 2025, marking its first submission date. Primary results and full study completion are anticipated within the next few years, subject to ongoing patient enrollment and updates.
This clinical update reinforces Argenx’s commitment to advancing SMA treatments, potentially strengthening investor confidence. Competitors in the SMA space, such as Biogen and Roche, may closely monitor progress as the market anticipates breakthroughs that could alter the competitive landscape.
The study remains in the not yet recruiting phase. Further details are available on the ClinicalTrials portal.
To learn more about ARGX’s potential, visit the Argenx drug pipeline page.